In­tra-Cel­lu­lar re­ports a de­pres­sion win, set­ting up fu­ture com­pe­ti­tion with Ab­b­Vie's Vray­lar

In­tra-Cel­lu­lar Ther­a­pies has nailed a sec­ond Phase 3 study test­ing its an­tipsy­chot­ic med­ica­tion Caply­ta as an ad­junc­tive treat­ment for ma­jor de­pres­sion.

Next, it plans to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.